Current experimental and early investigational agents for cardiac fibrosis: where are we at?

References

• Schellings MW, Pinto YM, Heymans S. Matricellular proteins in the heart: possible role during stress and remodeling. Cardiovasc Res. 2004;64(1):24–31. doi: 10.1016/j.cardiores.2004.06.006
   PubMed Web of Science ®Google Scholar
• Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol. 2008;214(2):199–210. doi: 10.1002/path.2277
   PubMed Web of Science ®Google Scholar
• Pucci A, Aimo A, Musetti V, et al. Amyloid deposits and fibrosis on left ventricular endomyocardial biopsy correlate with extracellular volume in cardiac amyloidosis. J Am Heart Assoc. 2021;10(20):e020358. doi: 10.1161/JAHA.120.020358
   PubMed Web of Science ®Google Scholar
• Schimmel K, Ichimura K, Reddy S, et al. Cardiac fibrosis in the pressure overloaded left and right ventricle as a therapeutic target. Front Cardiovasc Med. 2022 May 6;9:886553. doi: 10.3389/fcvm.2022.886553
   PubMed Web of Science ®Google Scholar
• de Boer RA, De Keulenaer G, Bauersachs J, et al. Towards better definition, quantification and treatment of fibrosis in heart failure. A scientific roadmap by the committee of translational research of the heart failure Association (HFA) of the European society of cardiology. Eur J Heart Fail. 2019;21(3):272–285. doi: 10.1002/ejhf.1406
   PubMed Web of Science ®Google Scholar
• Kai H, Mori T, Tokuda K, et al. Pressure overload-induced transient oxidative stress mediates perivascular inflammation and cardiac fibrosis through angiotensin II. Hypertens Res. 2006;29(9):711–718. doi: 10.1291/hypres.29.711
   PubMed Web of Science ®Google Scholar
• Talman V, Ruskoaho H. Cardiac fibrosis in myocardial infarction-from repair and remodeling to regeneration. Cell Tissue Res. 2016;365(3):563–581. doi: 10.1007/s00441-016-2431-9
   PubMed Web of Science ®Google Scholar
• Kong P, Christia P, Frangogiannis NG. The pathogenesis of cardiac fibrosis. Cell Mol Life Sci. 2014;71(4):549–574. doi: 10.1007/s00018-013-1349-6
   PubMed Web of Science ®Google Scholar
• Creemers EE, Pinto YM. Molecular mechanisms that control interstitial fibrosis in the pressure-overloaded heart. Cardiovasc Res. 2011;89(2):265–272. doi: 10.1093/cvr/cvq308
   PubMed Web of Science ®Google Scholar
• Spoladore R, Falasconi G, Fiore G, et al. Cardiac fibrosis: emerging agents in preclinical and clinical development. Expert Opin Investig Drugs. 2021;30(2):153–166. doi: 10.1080/13543784.2021.1868432
   PubMed Web of Science ®Google Scholar
• Kulasekaran P, Scavone CA, Rogers DS, et al. Endothelin-1 and transforming growth factor-beta1 independently induce fibroblast resistance to apoptosis via AKT activation. Am J Respir Cell Mol Biol. 2009;41(4):484–493. doi: 10.1165/rcmb.2008-0447OC
   PubMed Web of Science ®Google Scholar
• Hinderer S, Schenke-Layland K. Cardiac fibrosis - a short review of causes and therapeutic strategies. Adv Drug Deliv Rev. 2019;146:77–82. doi: 10.1016/j.addr.2019.05.011
   PubMed Web of Science ®Google Scholar
• Iles L, Pfluger H, Phrommintikul A, et al. Evaluation of diffuse myocardial fibrosis in heart failure with cardiac magnetic resonance contrast-enhanced T1 mapping. J Am Coll Cardiol. 2008;52(19):1574–1580. doi: 10.1016/j.jacc.2008.06.049
   PubMed Web of Science ®Google Scholar
• de Boer RA, Daniels LB, Maisel AS, et al. State of the art: newer biomarkers in heart failure. Eur J Heart Fail. 2015;17(6):559–569. doi: 10.1002/ejhf.273
   PubMed Web of Science ®Google Scholar
• López B, González A, Ravassa S, et al. Circulating biomarkers of myocardial fibrosis: the need for a reappraisal. J Am Coll Cardiol. 2015;65(22):2449–2456. doi: 10.1016/j.jacc.2015.04.026
   PubMed Web of Science ®Google Scholar
• Oakes RS, Badger TJ, Kholmovski EG, et al. Detection and quantification of left atrial structural remodeling with delayed-enhancement magnetic resonance imaging in patients with atrial fibrillation. Circulation. 2009;119(13):1758–1767. doi: 10.1161/CIRCULATIONAHA.108.811877
   PubMed Web of Science ®Google Scholar
• O’Hanlon R, Grasso A, Roughton M, et al. Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2010;56(11):867–874. doi: 10.1016/j.jacc.2010.05.010
   PubMed Web of Science ®Google Scholar
• Zegard A, Okafor O, de Bono J, et al. Myocardial fibrosis as a predictor of sudden death in patients with coronary artery disease. J Am Coll Cardiol. 2021;77(1):29–41. doi: 10.1016/j.jacc.2020.10.046
   PubMed Web of Science ®Google Scholar
• Schirone L, Forte M, Palmerio S, et al. A review of the molecular mechanisms underlying the development and progression of cardiac remodeling. Oxid Med Cell Longev. 2017;2017:3920195. doi: 10.1155/2017/3920195
   PubMed Web of Science ®Google Scholar
• Schnee JM, Hsueh WA. Angiotensin II, adhesion, and cardiac fibrosis. Cardiovasc Res. 2000;46(2):264–268. doi: 10.1016/s0008-6363(00)00044-4
   PubMed Web of Science ®Google Scholar
• Varo N, Iraburu MJ, Varela M, et al. Chronic AT(1) blockade stimulates extracellular collagen type I degradation and reverses myocardial fibrosis in spontaneously hypertensive rats. Hypertension. 2000;35(6):1197–1202. doi: 10.1161/01.hyp.35.6.1197
   PubMed Web of Science ®Google Scholar
• Brilla CG, Funck RC, Rupp H. Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation. 2000;102(12):1388–1393. doi: 10.1161/01.cir.102.12.1388
   PubMed Web of Science ®Google Scholar
• López B, Querejeta R, Varo N, et al. Usefulness of serum carboxy-terminal propeptide of procollagen type I in assessment of the cardioreparative ability of antihypertensive treatment in hypertensive patients. Circulation. 2001;104(3):286–291. doi: 10.1161/01.cir.104.3.286
   PubMed Web of Science ®Google Scholar
• Díez J, Querejeta R, López B, et al. Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. Circulation. 2002;105(21):2512–2517. doi: 10.1161/01.cir.0000017264.66561.3d
   PubMed Web of Science ®Google Scholar
• Soberman JE, Weber KT. Spironolactone in congestive heart failure. Curr Hypertens Rep. 2000;2(5):451–456. doi: 10.1007/s11906-000-0027-x
   PubMedGoogle Scholar
• Kosmala W, Przewlocka-Kosmala M, Szczepanik-Osadnik H, et al. A randomized study of the beneficial effects of aldosterone antagonism on LV function, structure, and fibrosis markers in metabolic syndrome. JACC Cardiovasc Imaging. 2011;4(12):1239–1249. doi: 10.1016/j.jcmg.2011.08.014
   PubMed Web of Science ®Google Scholar
• Kosmala W, Przewlocka-Kosmala M, Szczepanik-Osadnik H, et al. Fibrosis and cardiac function in obesity: a randomised controlled trial of aldosterone blockade. Heart. 2013;99(5):320–326. doi: 10.1136/heartjnl-2012-303329
   PubMed Web of Science ®Google Scholar
• Mak GJ, Ledwidge MT, Watson CJ, et al. Natural history of markers of collagen turnover in patients with early diastolic dysfunction and impact of eplerenone. J Am Coll Cardiol. 2009;54(18):1674–1682. doi: 10.1016/j.jacc.2009.08.021
   PubMed Web of Science ®Google Scholar
• Deswal A, Richardson P, Bozkurt B, et al. Results of the randomized aldosterone antagonism in heart failure with preserved ejection fraction trial (RAAM-PEF). J Card Fail. 2011;17(8):634–642. doi: 10.1016/j.cardfail.2011.04.007
   PubMed Web of Science ®Google Scholar
• Zannad F, Alla F, Dousset B, et al. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators [published correction appears in circulation 2001 Jan 23;103(3): 476]. Circulation. 2000;102(22):2700–2706. doi: 10.1161/01.cir.102.22.2700
   PubMed Web of Science ®Google Scholar
• Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N Engl J Med. 1999;341(10):709–717. doi: 10.1056/NEJM199909023411001
   PubMed Web of Science ®Google Scholar
• Hofmann F. A concise discussion of the regulatory role of cGMP kinase I in cardiac physiology and pathology. Basic Res Cardiol. 2018 Jun 22;113(4):31. doi: 10.1007/s00395-018-0690-1
   PubMed Web of Science ®Google Scholar
• Matei AE, Beyer C, Györfi AH, et al. Protein kinases G are essential downstream mediators of the antifibrotic effects of sGC stimulators. Ann Rheum Dis. 2018;77(3):459. doi: 10.1136/annrheumdis-2017-212489
   PubMed Web of Science ®Google Scholar
• Nakerakanti S, Trojanowska M. The role of TGF-β receptors in fibrosis. Open Rheumatol J. 2012;6(1):156–162. doi: 10.2174/1874312901206010156
   PubMedGoogle Scholar
• Burke RM, Lighthouse JK, Mickelsen DM, et al. Sacubitril/Valsartan decreases cardiac fibrosis in left ventricle pressure overload by restoring PKG signaling in cardiac fibroblasts. Circ Heart Fail. 2019;12(4):e005565. doi: 10.1161/CIRCHEARTFAILURE.118.005565
   PubMed Web of Science ®Google Scholar
• Kapoun AM, Liang F, O’Young G, et al. B-type natriuretic peptide exerts broad functional opposition to transforming growth factor-beta in primary human cardiac fibroblasts: fibrosis, myofibroblast conversion, proliferation, and inflammation. Circ Res. 2004;94(4):453–461. doi: 10.1161/01.RES.0000117070.86556.9F
   PubMed Web of Science ®Google Scholar
• McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993–1004. doi: 10.1056/NEJMoa1409077
   PubMed Web of Science ®Google Scholar
• Schmieder RE, Wagner F, Mayr M, et al. The effect of sacubitril/valsartan compared to olmesartan on cardiovascular remodelling in subjects with essential hypertension: the results of a randomized, double-blind, active-controlled study. Eur Heart J. 2017;38(44):3308–3317. doi: 10.1093/eurheartj/ehx525
   PubMed Web of Science ®Google Scholar
• Zile MR, O’Meara E, Claggett B, et al. Effects of sacubitril/valsartan on biomarkers of extracellular matrix regulation in patients with HFrEF. J Am Coll Cardiol. 2019;73(7):795–806. doi: 10.1016/j.jacc.2018.11.042
   PubMed Web of Science ®Google Scholar
• Solomon SD, McMurray JJV, Anand IS, et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med. 2019;381(17):1609–1620. doi: 10.1056/NEJMoa1908655
   PubMed Web of Science ®Google Scholar
• Cunningham JW, Claggett BL, O’Meara E, et al. Effect of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients With HFpEF. J Am Coll Cardiol. 2020;76(5):503–514. doi: 10.1016/j.jacc.2020.05.072
   PubMed Web of Science ®Google Scholar
• Bodey F, Hopper I, Krum H. Neprilysin inhibitors preserve renal function in heart failure. Int J Cardiol. 2015;179:329–330. doi: 10.1016/j.ijcard.2014.11.059
   PubMed Web of Science ®Google Scholar
• Jordan J, Stinkens R, Jax T, et al. Improved insulin sensitivity with angiotensin receptor neprilysin inhibition in individuals with obesity and hypertension. Clin Pharmacol Ther. 2017;101(2):254–263. doi: 10.1002/cpt.455
   PubMed Web of Science ®Google Scholar
• Mazurek JA, Jessup M. Understanding Heart Failure. Card Electrophysiol Clin. 2015;7(4):557–575. doi: 10.1016/j.ccep.2015.08.001
   PubMedGoogle Scholar
• Le DE, Pascotto M, Leong-Poi H, et al. Anti-inflammatory and pro-angiogenic effects of beta blockers in a canine model of chronic ischemic cardiomyopathy: comparison between carvedilol and metoprolol. Basic Res Cardiol. 2013;108(6):384. doi: 10.1007/s00395-013-0384-7
   PubMed Web of Science ®Google Scholar
• Ziegler KA, Ahles A, Wille T, et al. Local sympathetic denervation attenuates myocardial inflammation and improves cardiac function after myocardial infarction in mice. Cardiovasc Res. 2018;114(2):291–299. doi: 10.1093/cvr/cvx227
   PubMed Web of Science ®Google Scholar
• Lin TT, Sung YL, Syu JY, et al. Anti-inflammatory and antiarrhythmic effects of beta blocker in a rat model of rheumatoid arthritis. J Am Heart Assoc. 2020;9(18):e016084. doi: 10.1161/JAHA.120.016084
   PubMed Web of Science ®Google Scholar
• Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015;373(22):2117–2128. doi: 10.1056/NEJMoa1504720
   PubMed Web of Science ®Google Scholar
• McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995–2008. doi: 10.1056/NEJMoa1911303
   PubMed Web of Science ®Google Scholar
• Packer M, Anker SD, Butler J, et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med. 2020;383(15):1413–1424. doi: 10.1056/NEJMoa2022190
   PubMed Web of Science ®Google Scholar
• Solomon SD, de Boer RA, DeMets D, et al. Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial. Eur J Heart Fail. 2021;23(7):1217–1225. doi: 10.1002/ejhf.2249
   PubMed Web of Science ®Google Scholar
• Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451–1461. doi: 10.1056/NEJMoa2107038
   PubMed Web of Science ®Google Scholar
• Lee HC, Shiou YL, Jhuo SJ, et al. The sodium-glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats. Cardiovasc Diabetol. 2019 Apr 1;18(1):45. doi: 10.1186/s12933-019-0849-6
   PubMedGoogle Scholar
• Li C, Zhang J, Xue M, et al. SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart. Cardiovasc Diabetol. 2019 Feb 2;18(1):15. doi: 10.1186/s12933-019-0816-2
   PubMedGoogle Scholar
• Kang S, Verma S, Hassanabad AF, et al. Direct Effects of Empagliflozin on Extracellular Matrix Remodelling in Human Cardiac Myofibroblasts: Novel Translational Clues to Explain EMPA-REG OUTCOME Results. Can J Cardiol. 2020;36(4):543–553. doi: 10.1016/j.cjca.2019.08.033
   PubMed Web of Science ®Google Scholar
• Santos-Gallego CG, Requena-Ibanez JA, San Antonio R, et al. Empagliflozin ameliorates adverse left ventricular remodeling in nondiabetic Heart failure by enhancing myocardial energetics. J Am Coll Cardiol. 2019;73(15):1931–1944. doi: 10.1016/j.jacc.2019.01.056
   PubMed Web of Science ®Google Scholar
• Santos-Gallego CG, Requena-Ibanez JA, San Antonio R, et al. Empagliflozin Ameliorates Diastolic Dysfunction and Left Ventricular Fibrosis/Stiffness in Nondiabetic Heart Failure: A Multimodality Study. JACC Cardiovasc Imaging. 2021;14(2):393–407. doi: 10.1016/j.jcmg.2020.07.042
   PubMed Web of Science ®Google Scholar
• Lee TM, Chang NC, Lin SZ. Dapagliflozin, a selective SGLT2 Inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts. Free Radic Biol Med. 2017;104:298–310. doi: 10.1016/j.freeradbiomed.2017.01.035
   PubMed Web of Science ®Google Scholar
• Ye Y, Jia X, Bajaj M, et al. Dapagliflozin attenuates Na+/H+ exchanger-1 in Cardiofibroblasts via AMPK activation. Cardiovasc Drugs Ther. 2018;32(6):553–558. doi: 10.1007/s10557-018-6837-3
   PubMed Web of Science ®Google Scholar
• Wang K, Li Z, Sun Y, et al. Dapagliflozin Improves Cardiac Function, Remodeling, Myocardial Apoptosis, and Inflammatory Cytokines in Mice with Myocardial Infarction. J Cardiovasc Transl Res. 2022;15(4):786–796. doi: 10.1007/s12265-021-10192-y
   PubMed Web of Science ®Google Scholar
• Daud E, Ertracht O, Bandel N, et al. The impact of empagliflozin on cardiac physiology and fibrosis early after myocardial infarction in non-diabetic rats. Cardiovasc Diabetol. 2021 Jul 2;20(1):132. doi: 10.1186/s12933-021-01322-6
   PubMed Web of Science ®Google Scholar
• Wang C, Qin Y, Zhang X, et al. Effect of Dapagliflozin on indicators of myocardial fibrosis and levels of inflammatory factors in heart failure patients. Disease Markers. 2022 Sep 5;2022:1–7.
   Web of Science ®Google Scholar
• McDonagh TA, Metra M, Adamo M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure [published correction appears in eur heart J. 2021 Oct 14. Eur Heart J. 2021;42(36):3599–3726. doi: 10.1093/eurheartj/ehab368
   PubMed Web of Science ®Google Scholar
• Yamamoto C, Fukuda N, Jumabay M, et al. Protective effects of statin on cardiac fibrosis and apoptosis in adrenomedullin-knockout mice treated with angiotensin II and high salt loading. Hypertens Res. 2011;34(3):348–353. doi: 10.1038/hr.2010.243
   PubMed Web of Science ®Google Scholar
• Wolfrum S, Dendorfer A, Rikitake Y, et al. Inhibition of Rho-kinase leads to rapid activation of phosphatidylinositol 3-kinase/protein kinase akt and cardiovascular protection. Arterioscler Thromb Vasc Biol. 2004;24(10):1842–1847. doi: 10.1161/01.ATV.0000142813.33538.82
   PubMed Web of Science ®Google Scholar
• Chang SA, Kim YJ, Lee HW, et al. Effect of rosuvastatin on cardiac remodeling, function, and progression to heart failure in hypertensive heart with established left ventricular hypertrophy. Hypertension. 2009;54(3):591–597. doi: 10.1161/HYPERTENSIONAHA.109.131243
   PubMed Web of Science ®Google Scholar
• Yu B, Yu M, Zhang H, et al. Suppression of miR-143-3p contributes to the anti-fibrosis effect of atorvastatin on myocardial tissues via the modulation of Smad2 activity. Exp Mol Pathol. 2020;112:104346. doi: 10.1016/j.yexmp.2019.104346
   PubMed Web of Science ®Google Scholar
• Abulhul E, McDonald K, Martos R, et al. Long-term statin therapy in patients with systolic heart failure and normal cholesterol: effects on elevated serum markers of collagen turnover, inflammation, and B-type natriuretic peptide. Clin Ther. 2012;34(1):91–100. doi: 10.1016/j.clinthera.2011.11.002
   PubMed Web of Science ®Google Scholar
• Chang YY, Wu YW, Lee JK, et al. Effects of 12 weeks of atorvastatin therapy on myocardial fibrosis and circulating fibrosis biomarkers in statin-naïve patients with hypertension with atherosclerosis. J Investig Med. 2016;64(7):1194–1199. doi: 10.1136/jim-2016-000092
   PubMed Web of Science ®Google Scholar
• Ashton E, Windebank E, Skiba M, et al. Why did high-dose rosuvastatin not improve cardiac remodeling in chronic heart failure? Mechanistic insights from the UNIVERSE study. Int J Cardiol. 2011;146(3):404–407. doi: 10.1016/j.ijcard.2009.12.028
   PubMed Web of Science ®Google Scholar
• Tavazzi L, Maggioni AP, Marchioli R, et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372(9645):1231–1239. doi: 10.1016/S0140-6736(08)61240-4
   PubMed Web of Science ®Google Scholar
• Kjekshus J, Apetrei E, Barrios V, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med. 2007;357(22):2248–2261. doi: 10.1056/NEJMoa0706201
   PubMed Web of Science ®Google Scholar
• Kim HB, Hong YJ, Park HJ, et al. Effects of Ivabradine on left ventricular systolic function and cardiac fibrosis in rat myocardial ischemia-reperfusion Model. Chonnam Med J. 2018;54(3):167–172. doi: 10.4068/cmj.2018.54.3.167
   PubMedGoogle Scholar
• Ma D, Xu T, Cai G, et al. Effects of ivabradine hydrochloride combined with trimetazidine on myocardial fibrosis in rats with chronic heart failure. Exp Ther Med. 2019;18(3):1639–1644. doi: 10.3892/etm.2019.7730
   PubMed Web of Science ®Google Scholar
• Simko F, Baka T, Poglitsch M, et al. Effect of Ivabradine on a hypertensive heart and the renin-angiotensin-aldosterone system in L-NAME-Induced hypertension. Int J Mol Sci. 2018 Oct 3;19(10):3017. doi: 10.3390/ijms19103017
   PubMed Web of Science ®Google Scholar
• Sjögren B, Parra S, Heath LJ, et al. Cardiotonic steroids stabilize regulator of G protein signaling 2 protein levels. Mol Pharmacol. 2012;82(3):500–509. doi: 10.1124/mol.112.079293
   PubMed Web of Science ®Google Scholar
• Nance MR, Kreutz B, Tesmer VM, et al. Structural and functional analysis of the regulator of G protein signaling 2-gαq complex. Structure. 2013;21(3):438–448. doi: 10.1016/j.str.2012.12.016
   PubMed Web of Science ®Google Scholar
• Sjögren B, Parra S, Atkins KB, et al. Digoxin-mediated upregulation of RGS2 protein protects against cardiac injury. J Pharmacol Exp Ther. 2016;357(2):311–319. doi: 10.1124/jpet.115.231571
   PubMed Web of Science ®Google Scholar
• Armstrong PW, Pieske B, Anstrom KJ, et al. Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med. 2020;382(20):1883–1893. doi: 10.1056/NEJMoa1915928
   PubMed Web of Science ®Google Scholar
• Geschka S, Kretschmer A, Sharkovska Y, et al. Soluble guanylate cyclase stimulation prevents fibrotic tissue remodeling and improves survival in salt-sensitive Dahl rats. PLoS One. 2011;6(7):e21853. doi: 10.1371/journal.pone.0021853
   PubMed Web of Science ®Google Scholar
• Sandner P. From molecules to patients: exploring the therapeutic role of soluble guanylate cyclase stimulators. Biol Chem. 2018;399(7):679–690. doi: 10.1515/hsz-2018-0155
   PubMed Web of Science ®Google Scholar
• Bice JS, Keim Y, Stasch JP, et al. NO-independent stimulation or activation of soluble guanylyl cyclase during early reperfusion limits infarct size. Cardiovasc Res. 2014;101(2):220–228. doi: 10.1093/cvr/cvt257
   PubMed Web of Science ®Google Scholar
• Methner C, Buonincontri G, Hu CH, et al. Riociguat reduces infarct size and post-infarct heart failure in mouse hearts: insights from MRI/PET imaging. PLoS One. 2013 Dec 31;8(12):e83910. doi: 10.1371/journal.pone.0083910
   PubMed Web of Science ®Google Scholar
• Adler Y, Charron P, Imazio M, et al. 2015 ESC guidelines for the diagnosis and management of pericardial diseases: the task force for the diagnosis and management of pericardial diseases of the European society of cardiology (esc)endorsed by: the European Association for cardio-thoracic surgery (EACTS). Eur Heart J. 2015;36(42):2921–2964. doi: 10.1093/eurheartj/ehv318
   PubMed Web of Science ®Google Scholar
• Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice [published correction appears in Eur Heart J. 2022 Nov 7;43(42):4468]. Eur Heart J. 2021;42(34): 3227–3337. doi: 10.1093/eurheartj/ehab484
   PubMedGoogle Scholar
• Roubille F, Kritikou E, Busseuil D, et al. Colchicine: an old wine in a new bottle? Antiinflamm Antiallergy Agents Med Chem. 2013;12(1):14–23. doi: 10.2174/1871523011312010004
   PubMedGoogle Scholar
• Akodad M, Fauconnier J, Sicard P, et al. Interest of colchicine in the treatment of acute myocardial infarct responsible for heart failure in a mouse model. Int J Cardiol. 2017;240:347–353. doi: 10.1016/j.ijcard.2017.03.126
   PubMed Web of Science ®Google Scholar
• Aimo A, Martinez-Falguera D, Barison A, et al. Colchicine added to standard therapy further reduces fibrosis in pigs with myocardial infarction. J Cardiovasc Med (Hagerstown). 2023;24(11):840–846. doi: 10.2459/JCM.0000000000001554
   PubMed Web of Science ®Google Scholar
• Akodad M, Sicard P, Fauconnier J, et al. Colchicine and myocardial infarction: a review. Arch Cardiovasc Dis. 2020;113(10):652–659. doi: 10.1016/j.acvd.2020.04.007
   PubMed Web of Science ®Google Scholar
• Tardif JC, Kouz S, Waters DD, et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med. 2019;381(26):2497–2505. doi: 10.1056/NEJMoa1912388
   PubMed Web of Science ®Google Scholar
• Mewton N, Roubille F, Bresson D, et al. Effect of Colchicine on Myocardial Injury in Acute Myocardial Infarction. Circulation. 2021;144(11):859–869. doi: 10.1161/CIRCULATIONAHA.121.056177
   PubMed Web of Science ®Google Scholar
• Bouros D. Pirfenidone for idiopathic pulmonary fibrosis. Lancet. 2011;377(9779):1727–1729. doi: 10.1016/S0140-6736(11)60546-1
   PubMed Web of Science ®Google Scholar
• Aimo A, Spitaleri G, Panichella G, et al. A. Pirfenidone as a novel cardiac protective treatment. Heart Fail Rev. 2022;27(2):525–532. doi: 10.1007/s10741-021-10175-w
   PubMed Web of Science ®Google Scholar
• Oku H, Shimizu T, Kawabata T, et al. Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis. Eur J Pharmacol. 2008;590(1–3):400–408. doi: 10.1016/j.ejphar.2008.06.046
   PubMed Web of Science ®Google Scholar
• Shi Q, Liu X, Bai Y, et al. In vitro effects of pirfenidone on cardiac fibroblasts: proliferation, myofibroblast differentiation, migration and cytokine secretion. PLoS One. 2011;6(11):e28134. doi: 10.1371/journal.pone.0028134
   PubMed Web of Science ®Google Scholar
• Aimo A, Cerbai E, Bartolucci G, et al. Pirfenidone is a cardioprotective drug: mechanisms of action and preclinical evidence. Pharmacol Res. 2020;155:104694. doi: 10.1016/j.phrs.2020.104694
   PubMed Web of Science ®Google Scholar
• Visner GA, Liu F, Bizargity P, et al. Pirfenidone inhibits T-cell activation, proliferation, cytokine and chemokine production, and host alloresponses. Transplantation. 2009;88(3):330–338. doi: 10.1097/TP.0b013e3181ae3392
   PubMed Web of Science ®Google Scholar
• Aimo A, Burchielli S, Barison A, et al. Effects of pirfenidone on scar size and ventricular remodeling after myocardial infarction: a preclinical study. J Cardiovasc Med (Hagerstown). 2023;24(12):880–890. doi: 10.2459/JCM.0000000000001534
   PubMed Web of Science ®Google Scholar
• Wang Y, Wu Y, Chen J, et al. Pirfenidone attenuates cardiac fibrosis in a mouse model of TAC-induced left ventricular remodeling by suppressing NLRP3 inflammasome formation. Cardiol. 2013;126(1):1–11. doi: 10.1159/000351179
   PubMed Web of Science ®Google Scholar
• Yamazaki T, Yamashita N, Izumi Y, et al. The antifibrotic agent pirfenidone inhibits angiotensin II-induced cardiac hypertrophy in mice. Hypertens Res. 2012;35(1):34–40. doi: 10.1038/hr.2011.139
   PubMed Web of Science ®Google Scholar
• AlAnsari H, Southern B, Riaz H, et al. Responses to Pirfenidone Treatment in patients with idiopathic pulmonary fibrosis is not associated with changes in echocardiographic parameters of left ventricular structure and function. J Card Fail. 2019;25(8):S27. doi: 10.1016/j.cardfail.2019.07.074
   PubMed Web of Science ®Google Scholar
• AlAnsari S, Southern BD, Sharma V, et al. Pirfenidone is associated with decreased indexed end diastolic and systolic volumes in patients with HFpEF and a known history of idiopathic pulmonary fibrosis [abstract]. J Card Fail. 2020;26(Suppl):S25. doi: 10.1016/j.cardfail.2020.09.080
   Google Scholar
• Lewis GA, Dodd S, Clayton D, et al. Pirfenidone in heart failure with preserved ejection fraction: a randomized phase 2 trial. Nat Med. 2021;27(8):1477–1482. doi: 10.1038/s41591-021-01452-0
   PubMed Web of Science ®Google Scholar
• Frangogiannis NG. Cardiac fibrosis. Cardiovasc Res. 2021;117(6):1450–1488. doi: 10.1093/cvr/cvaa324
   PubMed Web of Science ®Google Scholar
• Fang L, Murphy AJ, Dart AM. A clinical perspective of anti-fibrotic therapies for cardiovascular disease. Front Pharmacol. 2017 Apr 6;8:186. doi: 10.3389/fphar.2017.00186
   PubMed Web of Science ®Google Scholar
• Frantz S, Hu K, Adamek A, et al. Transforming growth factor beta inhibition increases mortality and left ventricular dilatation after myocardial infarction. Basic Res Cardiol. 2008;103(5):485–492. doi: 10.1007/s00395-008-0739-7
   PubMed Web of Science ®Google Scholar
• Kuwahara F, Kai H, Tokuda K, et al. Transforming growth factor-beta function blocking prevents myocardial fibrosis and diastolic dysfunction in pressure-overloaded rats. Circulation. 2002;106(1):130–135. doi: 10.1161/01.cir.0000020689.12472.e0
   PubMed Web of Science ®Google Scholar
• Verkerke H, Dias-Baruffi M, Cummings RD, et al. Galectins: An Ancient Family of Carbohydrate Binding Proteins with Modern Functions. Methods Mol Biol. 2022;2442:1–40. doi: 10.1007/978-1-0716-2055-7_1
   PubMedGoogle Scholar
• Sharma UC, Pokharel S, van Brakel TJ, et al. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation. 2004;110(19):3121–3128. doi: 10.1161/01.CIR.0000147181.65298.4D
   PubMed Web of Science ®Google Scholar
• Liu YH, D’Ambrosio M, Liao TD, et al. N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growth-regulatory lectin. Am J Physiol Heart Circ Physiol. 2009;296(2):H404–H412. doi: 10.1152/ajpheart.00747.2008
   PubMed Web of Science ®Google Scholar
• Kanasaki M, Nagai T, Kitada M, et al. Elevation of the antifibrotic peptide N-acetyl-seryl-aspartyl-lysyl-proline: a blood pressure-independent beneficial effect of angiotensin I-converting enzyme inhibitors. Fibrogenesis Tissue Repair. 2011 Nov 30;4(1):25. doi: 10.1186/1755-1536-4-25
   PubMedGoogle Scholar
• Rousseau A, Michaud A, Chauvet MT, et al. The hemoregulatory peptide N-acetyl-ser-asp-lys-pro is a natural and specific substrate of the N-terminal active site of human angiotensin-converting enzyme. J Biol Chem. 1995;270(8):3656–3661. doi: 10.1074/jbc.270.8.3656
   PubMed Web of Science ®Google Scholar
• Li P, Xiao HD, Xu J, et al. Angiotensin-converting enzyme N-terminal inactivation alleviates bleomycin-induced lung injury. Am J Pathol. 2010;177(3):1113–1121. doi: 10.2353/ajpath.2010.081127
   PubMed Web of Science ®Google Scholar
• Sun M, Chen M, Dawood F, et al. Tumor necrosis factor-alpha mediates cardiac remodeling and ventricular dysfunction after pressure overload state. Circulation. 2007;115(11):1398–1407. doi: 10.1161/CIRCULATIONAHA.106.643585
   PubMed Web of Science ®Google Scholar
• Mann DL, McMurray JJ, Packer M, et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the randomized etanercept worldwide evaluation (RENEWAL). Circulation. 2004;109(13):1594–1602. doi: 10.1161/01.CIR.0000124490.27666.B2
   PubMed Web of Science ®Google Scholar
• Chung ES, Packer M, Lo KH, et al. Anti-TNF therapy against congestive heart failure investigators. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF therapy against congestive heart failure (ATTACH) trial. Circulation. 2003;107(25):3133–3140. doi: 10.1161/01.CIR.0000077913.60364.D2
   PubMed Web of Science ®Google Scholar
• Hamid T, Gu Y, Ortines RV, et al. Divergent tumor necrosis factor receptor-related remodeling responses in heart failure: role of nuclear factor-kappaB and inflammatory activation. Circulation. 2009;119(10):1386–1397. doi: 10.1161/CIRCULATIONAHA.108.802918
   PubMed Web of Science ®Google Scholar
• Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet. 1999;353(9169):2001–2007. doi: 10.1016/S0140-6736(99)04440-2
   PubMed Web of Science ®Google Scholar
• Travers JG, Tharp CA, Rubino M, et al. Therapeutic targets for cardiac fibrosis: from old school to next-gen. J Clin Invest. 2022;132(5):e148554. doi: 10.1172/JCI148554
   PubMed Web of Science ®Google Scholar
• Sabbah HN. The cellular and physiologic effects of beta blockers in heart failure. Clin Cardiol. 1999;22 Suppl 5:V16–V20.
   PubMed Web of Science ®Google Scholar
• Liu X, Sun SQ, Hassid A, et al. cAMP inhibits transforming growth factor-beta-stimulated collagen synthesis via inhibition of extracellular signal-regulated kinase 1/2 and smad signaling in cardiac fibroblasts. Mol Pharmacol. 2006;70(6):1992–2003. doi: 10.1124/mol.106.028951
   PubMed Web of Science ®Google Scholar
• Yi XP, Gerdes AM, Li F. Myocyte redistribution of GRK2 and GRK5 in hypertensive, heart-failure-prone rats. Hypertension. 2002;39(6):1058–1063. doi: 10.1161/01.hyp.0000019130.09167.3b
   PubMed Web of Science ®Google Scholar
• Woodall MC, Woodall BP, Gao E, et al. Cardiac fibroblast GRK2 deletion enhances contractility and remodeling following Ischemia/Reperfusion injury. Circ Res. 2016;119(10):1116–1127. doi: 10.1161/CIRCRESAHA.116.309538
   PubMed Web of Science ®Google Scholar
• Raake PW, Schlegel P, Ksienzyk J, et al. AAV6.βARKct cardiac gene therapy ameliorates cardiac function and normalizes the catecholaminergic axis in a clinically relevant large animal heart failure model. Eur Heart J. 2013;34(19):1437–1447. doi: 10.1093/eurheartj/ehr447
   PubMed Web of Science ®Google Scholar
• Nantel F, Bonin H, Emorine LJ, et al. The human beta 3-adrenergic receptor is resistant to short term agonist-promoted desensitization. Mol Pharmacol. 1993;43(4):548–555.
   PubMed Web of Science ®Google Scholar
• Michel LYM, Farah C, Balligand JL. The Beta3 Adrenergic Receptor in Healthy and Pathological Cardiovascular Tissues. Cells. 2020 [Published 2020 Dec 2];9(12):2584. doi: 10.3390/cells9122584
   PubMed Web of Science ®Google Scholar
• Gong W, Yan M, Chen J, et al. Chronic inhibition of cyclic guanosine monophosphate-specific phosphodiesterase 5 prevented cardiac fibrosis through inhibition of transforming growth factor β-induced smad signaling. Front Med. 2014;8(4):445–455. doi: 10.1007/s11684-014-0378-3
   PubMed Web of Science ®Google Scholar
• Takimoto E, Champion HC, Li M, et al. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med. 2005;11(2):214–222. doi: 10.1038/nm1175
   PubMed Web of Science ®Google Scholar
• Pérez NG, Piaggio MR, Ennis IL, et al. Phosphodiesterase 5A inhibition induces Na+/H+ exchanger blockade and protection against myocardial infarction. Hypertension. 2007;49(5):1095–1103. doi: 10.1161/HYPERTENSIONAHA.107.087759
   PubMed Web of Science ®Google Scholar
• Pokreisz P, Vandenwijngaert S, Bito V, et al. Ventricular phosphodiesterase-5 expression is increased in patients with advanced heart failure and contributes to adverse ventricular remodeling after myocardial infarction in mice. Circulation. 2009;119(3):408–416. doi: 10.1161/CIRCULATIONAHA.108.822072
   PubMed Web of Science ®Google Scholar
• Gong W, Yan M, Chen J, et al. Chronic inhibition of cyclic guanosine monophosphate-specific phosphodiesterase 5 prevented cardiac fibrosis through inhibition of transforming growth factor β-induced smad signaling. Front Med. 2014;8(4):445–455. doi: 10.1007/s11684-014-0378-3
   PubMed Web of Science ®Google Scholar
• Salloum FN, Abbate A, Das A, et al. Sildenafil (viagra) attenuates ischemic cardiomyopathy and improves left ventricular function in mice. Am J Physiol Heart Circ Physiol. 2008;294(3):H1398–H1406. doi: 10.1152/ajpheart.ajpheart.91438.2007
   PubMed Web of Science ®Google Scholar
• Chau VQ, Salloum FN, Hoke NN, et al. Mitigation of the progression of heart failure with sildenafil involves inhibition of RhoA/Rho-kinase pathway. Am J Physiol Heart Circ Physiol. 2011;300(6):H2272–H2279. doi: 10.1152/ajpheart.00654.2010
   PubMed Web of Science ®Google Scholar
• Kim KH, Kim YJ, Ohn JH, et al. Long-term effects of sildenafil in a rat model of chronic mitral regurgitation: benefits of ventricular remodeling and exercise capacity. Circulation. 2012;125(11):1390–1401. doi: 10.1161/CIRCULATIONAHA.111.065300
   PubMed Web of Science ®Google Scholar
• Guazzi M, Vicenzi M, Arena R, et al. PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure: results of a 1-year, prospective, randomized, placebo-controlled study. Circ Heart Fail. 2011;4(1):8–17. doi: 10.1161/CIRCHEARTFAILURE.110.944694
   PubMed Web of Science ®Google Scholar
• Heymans S, Lupu F, Terclavers S, et al. Loss or inhibition of uPA or MMP-9 attenuates LV remodeling and dysfunction after acute pressure overload in mice. Am J Pathol. 2005;166(1):15–25. doi: 10.1016/S0002-9440(10)62228-6
   PubMed Web of Science ®Google Scholar
• Matsusaka H, Ide T, Matsushima S, et al. Targeted deletion of matrix metalloproteinase 2 ameliorates myocardial remodeling in mice with chronic pressure overload. Hypertension. 2006;47(4):711–717. doi: 10.1161/01.HYP.0000208840.30778.00
   PubMed Web of Science ®Google Scholar
• Hudson MP, Armstrong PW, Ruzyllo W, et al. Effects of selective matrix metalloproteinase inhibitor (PG-116800) to prevent ventricular remodeling after myocardial infarction: results of the PREMIER (prevention of myocardial infarction early remodeling) trial. J Am Coll Cardiol. 2006;48(1):15–20. doi: 10.1016/j.jacc.2006.02.055
   PubMed Web of Science ®Google Scholar
• Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021 Apr 6;11(4):69. doi: 10.1038/s41408-021-00459-7
   PubMed Web of Science ®Google Scholar
• Wang Z, Wu Z, Liu Y, et al. New development in CAR-T cell therapy. J Hematol Oncol. 2017 Feb 21;10(1):53. doi: 10.1186/s13045-017-0423-1
   PubMedGoogle Scholar
• Liu Y, Chen X, Han W, et al. Tisagenlecleucel, an approved anti-CD19 chimeric antigen receptor T-cell therapy for the treatment of leukemia. Drugs Today (Barc). 2017;53(11):597–608. doi: 10.1358/dot.2017.53.11.2725754
   PubMed Web of Science ®Google Scholar
• Aghajanian H, Kimura T, Rurik JG, et al. Targeting cardiac fibrosis with engineered T cells [published correction appears in nature. 2019 Dec;576(7785): E2]. Nature. 2019;573(7774):430–433. doi: 10.1038/s41586-019-1546-z
   PubMed Web of Science ®Google Scholar
• Sermer D, Brentjens R. CAR T-cell therapy: full speed ahead. Hematol Oncol. 2019;37 Suppl 1(S1):95–100. doi: 10.1002/hon.2591
   PubMedGoogle Scholar
• National Cancer Institute. CAR T cells: engineering patients’ immune cells to treat their cancer. Available from: https://www.cancer.gov/about-cancer/treatment/research/car-t-cells.
   Google Scholar
• Kalos M, Levine BL, Porter DL, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med. 2011;3(95):95ra73. doi: 10.1126/scitranslmed.3002842
   PubMed Web of Science ®Google Scholar
• Ghosh AK, Chen DH, Guha A, et al. CAR T Cell Therapy-Related Cardiovascular Outcomes and management: systemic disease or direct cardiotoxicity? JACC Cardio Oncol. 2020 Mar 17;2(1):97–109. doi: 10.1016/j.jaccao.2020.02.011
   PubMedGoogle Scholar
• Asnani A. Cardiotoxicity of immunotherapy: incidence, diagnosis, and management. Curr Oncol Rep. 2018 Apr 11;20(6):44. doi: 10.1007/s11912-018-0690-1
   PubMed Web of Science ®Google Scholar
• Rurik JG, Tombácz I, Yadegari A, et al. CAR T cells produced in vivo to treat cardiac injury. Science. 2022;375(6576):91–96. doi: 10.1126/science.abm0594
   PubMed Web of Science ®Google Scholar